Daily bolus injection frequency and engagement with a smart pen to administer insulin were associated with glycemic control among young adult patients with type 1 diabetes (T1D) in a real-world ...

The recommended dose is 30mg once daily administered by intravenous bolus injection over 15 seconds. Patients who receive Xifyrm should be monitored for analgesic response.

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID analgesics as part of a multimodal pain strategy. The FDA has approved Azurity ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has declined to approve ...

WOBURN, Mass., June 10, 2025 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRM™ (meloxicam injection), an IV non ...

The newer thrombolytic given as a bolus dose showed functional and safety outcomes similar to those of alteplase infusion in the NOR-TEST trial. ... and it can be given as one single bolus injection.